High levels of prostaglandin F2 alpha (PGF2α) are underlying causes of multiple diseases in the uterus, lung, and other organs.The rationale of selective antagonism of the PGF2α pathway as precision therapies for these conditions has been well established; they will work better and are also safer. However, despite three decades of discovery efforts by pharmaceutical companies, there is no approved drug to date that specifically targets the PGF2α pathway. In this backdrop, we have created potent small molecule antagonists of this pathway that have exquisite selectivity, without affecting other essential prostaglandin functions.
Science
